DNER and lung adenocarcinoma: Taken together with previous observations of anti-tumor activity in NMC, lung adenocarcinoma, glioblastoma, and a number of hematologic malignancies [11,12,16–18,33,34], our study highlights the potential of BET inhibitors like I-BET726 as effective therapeutic agents in a wide variety of cancers.